Nuclear imaging device maker Positron Corp. (OTC:POSC) touted a pair of wins coming from partnerships.

Late last week the Crown Point, Ind.-based company announced FDA approval for its new cfrQuant coronary flow reserve quantification software, which was developed by the University of Texas Health Science Center in Houston under the guidance of Positron’s Dr. Lance Gould.

Positron provided software segments for the program, which aims to provide a non-invasive vascular assessment, used in conjunction with cardiac PET imaging, for diagnosis and treatment of coronary disease.

Positron plans to distribute the software to current and future cardiac PET customers via a licensing agreement with UTHealth, according to a press release.

In a separate release, Positron also announced CE Mark approval in the European Union for the Attrius PET imaging system, a device developed by Neusoft Positron Medical Systems, a joint venture with Neusoft Medical Systems.

Theranos whistleblower Tyler Shultz to participate in keynote interview at DeviceTalks Boston At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos. Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston. REGISTER NOW